Leerink开始跑赢大盘后，Scholar Rock股价收盘上涨6%

2025-09-16 04:13

Scholar Rock Holding Corp. (NASDAQ:SRRK) closed Monday up ~6% after Leerink Partners initiated the biopharma at outperform citing optimism on approval for spinal muscular atrophy candidate apitegromab.
The asset has a US FDA action date of Sept. 22.
Leerink set a $51 price target (~51% upside based on Monday's close).
Analyst Mani Foroohar said that if apitegromab is approved on schedule and with a broad label for all SMA patients -- he gives that a 40% probability -- it would add $9 to the price target. A complete response letter, however, would cause $25 downside to the target.
Foroohar added there is a 50/50 chance the application will face a three-month action date extension given issues Scholar Rock has had with its contract development and manufacturing organization, Catalent, FDA staff turnover, and a prior FDA delay in approving two applications from Regeneron Pharmaceuticals (REGN) for Eylea HD. That product is also produced at a Catalent facility.
Novo Holdings (NVO) acquired Catalent in 2024.

More on Scholar Rock